Study of the evolution of Th17 immune response in patients with rheumatoid arthritis treated with tocilizumab and after failure of other therapies [Etude de l'evolution de la reponse immunitaire Th17 chez des patients atteints de polyarthrite rhumatoide et traites par tocilizumab apres echec des autres therapies]

Trial Profile

Study of the evolution of Th17 immune response in patients with rheumatoid arthritis treated with tocilizumab and after failure of other therapies [Etude de l'evolution de la reponse immunitaire Th17 chez des patients atteints de polyarthrite rhumatoide et traites par tocilizumab apres echec des autres therapies]

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Jun 2012

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Pharmacodynamics; Pharmacogenomic
  • Most Recent Events

    • 28 Jun 2012 Planned End Date changed to 31 Oct 2011.
    • 27 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top